Suchergebnisse - "Guaraldi, Giovanni"

PubPharm (16)

1

BEING : Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period

enthalten in: AIDS research and human retroviruses | 2023

von Walmsley, S. | Clarke, R. | Lee, T. | +7

2

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk : A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waters, L. | Assoumou, L. | González-Cordón, A. | +121

3

Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF : the DEBATE trial

enthalten in: Frontiers in immunology | 2023

von Cossarizza, A. | Cozzi-Lepri, A. | Mattioli, M. | +18

4

Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia : a double-blind, randomised, placebo-controlled trial

enthalten in: The European respiratory journal | 2022

von Salvarani, C. | Massari, M. | Costantini, M. | +42

CommentIn: Eur Respir J. 2022 Oct 20;60(4):. - PMID 35777764

5

Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir : a substudy of the NEAT022 study

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Saumoy, M. | Sánchez-Quesada, J. | Assoumou, L. | +12

6

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk : 48 week effects on subclinical cardiovascular disease

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Gonzalez-Cordon, A. | Assoumou, L. | Camafort, M. | +113

7

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years : Final 96-Week Results of the NEAT022 Study

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019

von Gatell, J. | Assoumou, L. | Moyle, G. | +124

8

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

enthalten in: AIDS (London, England) | 2017

von Gatell, J. | Assoumou, L. | Moyle, G. | +15

CommentIn: AIDS. 2017 Nov 28;31(18):2547-2549. - PMID 29120900

9

Atazanavir/ritonavir monotherapy : 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Galli, L. | Spagnuolo, V. | Bigoloni, A. | +55

10

Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults : the Monarch randomized controlled trial

enthalten in: International journal of STD & AIDS | 2014

von Guaraldi, G. | Zona, S. | Cossarizza, A. | +8